CAPOX 3 month

PreclinicalSmall molecule

NNRG Oncology

CAPOX 3 month is one of 5 small molecule programs targeting Stage III Colon Cancer. It is currently in Preclinical.

Indications

Total Trials

Active Trials

Competitors

Pipeline

Status by Indication[3][1]

Indication

Stage III Colon CancerRecruiting

Stage III Colon CancerPreclinical

Recruiting

Competition

Competitive Landscape

7 competitors in Stage III Colon Cancer

#DrugCompanyPhaseTrials

Mfolfirinox

Incyte

Phase 3

2 2

QL1706

Qilu Pharmaceutical Co., Ltd.

Phase 2

1 3

FOLFOXIRI

SSun Yat-sen University

Phase 2

1 4

Tegafur-Uracil

EEastern Cooperative Oncology Group

Preclinical

2 5

CAPOX 3 month

NNRG Oncology

Preclinical

Ranked by pipeline maturity and clinical activity. Current drug highlighted in teal.

Timeline

Expected Milestones

Q1 2030

PreclinicalRecruiting

Stage III Colon Cancer

NCT05174169

Clinical

Trials by Indication[1]

Stage III Colon Cancer1 trial

Colon Adjuvant Chemotherapy Based on Evaluation of Residual Disease

Recruiting·NNRG Oncology·Preclinical·NCT05174169·1,912 enrolled

Sources

References

[1]
ClinicalTrials.gov — 1 trial record for CAPOX 3 month. U.S. National Library of Medicine, National Institutes of Health.
[2]
ChEMBL — CAPOX 3 month compound record. European Bioinformatics Institute (EMBL-EBI).
[3]
Open Targets Platform — Drug–disease associations for CAPOX 3 month. EMBL-EBI & Wellcome Sanger Institute.
[4]
SEC EDGAR — NRG Oncology company filings. U.S. Securities and Exchange Commission.

Details

Drug Info

Quick Facts

Modality: Small molecule[2]
Highest Phase: Preclinical[1]
Company: NNRG Oncology

CAPOX 3 month

Status by Indication[3][1]

Competitive Landscape

Expected Milestones

Q1 2030

Trials by Indication[1]

Stage III Colon Cancer1 trial

References

Drug Info

Quick Facts

Related News